# AbbVie Inc. (ABBV)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $398.84B  
**Price:** $224.95 (-0.21%)

> AbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines and therapies worldwide. The company maintains a strong focus on immunology, offering treatments like Humira, Skyrizi, and Rinvoq for autoimmune and inflammatory conditions in rheumatology, gastroenterology, dermatology, and related areas. In oncology, it provides therapies such as Imbruvica, Venclexta, Elahere, Epkinly, and Emrelis targeting blood cancers, lymphoma, and lung cancer. AbbVie Inc. also addresses virology with Mavyret for hepatitis C, neuroscience for neurological disorders like Parkinson's, and additional areas including metabolic diseases, cystic fibrosis complications, endometriosis pain, irritable bowel syndrome, chronic constipation, and pancreatic enzyme therapy with Creon, alongside aesthetics products like Botox and Linzess/Constella. Founded in 2013 and headquartered in North Chicago, Illinois, AbbVie Inc. plays a vital role in the healthcare sector by delivering solutions for complex, chronic, and serious health conditions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $61.16B | $42.96B | $15.07B | $4.23B | $2.36 |
| 2024 | $56.33B | $39.43B | $9.14B | $4.28B | $2.39 |
| 2023 | $54.32B | $33.90B | $12.76B | $4.86B | $2.72 |
| 2022 | $58.05B | $40.64B | $18.12B | $11.84B | $6.63 |
| 2021 | $56.20B | $38.75B | $17.92B | $11.54B | $6.45 |
| 2020 | $45.80B | $30.42B | $11.36B | $4.62B | $2.72 |
| 2019 | $33.27B | $25.83B | $12.98B | $7.88B | $5.28 |
| 2018 | $32.75B | $25.04B | $6.38B | $5.69B | $3.66 |
| 2017 | $28.22B | $21.17B | $9.54B | $5.31B | $3.30 |
| 2016 | $25.64B | $19.81B | $9.34B | $5.95B | $3.63 |
| 2015 | $22.86B | $18.36B | $7.54B | $5.14B | $3.13 |
| 2014 | $19.96B | $15.53B | $3.41B | $1.77B | $1.10 |
| 2013 | $18.79B | $14.21B | $5.66B | — | $2.56 |
| 2012 | $18.38B | $13.87B | $5.82B | — | $3.35 |
| 2011 | $17.44B | $12.80B | $3.62B | — | $2.18 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $133.96B | $137.23B | -$3.27B | $5.23B | $64.50B |
| 2024 | $135.16B | $131.84B | $3.33B | $5.52B | $66.84B |
| 2023 | $134.71B | $124.35B | $10.36B | $12.81B | $59.24B |
| 2022 | $138.81B | $121.55B | $17.25B | $9.20B | $63.13B |
| 2021 | $146.53B | $131.12B | $15.41B | $9.75B | $75.96B |
| 2020 | $150.56B | $137.49B | $13.08B | $8.45B | $84.95B |
| 2019 | $89.11B | $97.29B | -$8.17B | $39.92B | $67.23B |
| 2018 | $59.35B | $67.80B | -$8.45B | $7.29B | — |
| 2017 | $70.79B | $65.69B | $5.10B | $9.30B | — |
| 2016 | $66.10B | $61.46B | $4.64B | $5.10B | — |
| 2015 | $53.05B | $49.10B | $3.94B | $8.40B | — |
| 2014 | $27.51B | $25.77B | $1.74B | $8.35B | — |
| 2013 | $29.20B | $24.71B | $4.49B | $9.60B | — |
| 2012 | $27.01B | $27.36B | -$350M | $5.90B | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $19.03B | $1.21B | $17.82B |
| 2024 | $18.81B | $974M | $17.83B |
| 2023 | $22.84B | $777M | $22.06B |
| 2022 | $24.94B | $695M | $24.25B |
| 2021 | $22.78B | $787M | $21.99B |
| 2020 | $17.59B | $798M | $16.79B |
| 2019 | $13.32B | $552M | $12.77B |
| 2018 | $13.43B | $638M | $12.79B |
| 2017 | $9.96B | $529M | $9.43B |

Source: [CompaniesByCap](https://companiesbycap.com/company/ABBV)